COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,790 Articles (22,523 medRxiv, 8,267 bioRxiv)

Most recent first Previous |  Page 971: Articles 9701-9710  | Next

Comparison of infectious SARS-CoV-2 from the nasopharynx of vaccinated and unvaccinated individuals
Pena-Hernandez, M. A., Klein, J., Malik, A., Coppi, A., Kalinich, C. C., Vogels, C. B. F., Silva, J., Yale SARS-CoV-2 Genomic Surveillance Initiative, , Peaper, D. R., Landry, M., Wilen, C., Grubaugh, N. D., Schulz, W. L., Omer, S. B., Iwasaki, A.
10.1101/2021.12.28.21268460 — Posted: 2022-01-04 Discussion: Onsite
The runaway evolution of SARS-CoV-2 leading to the highly evolved Delta strain
Ruan, Y., Hou, M., Tang, X., He, X., Lu, X., Lu, J., Wu, C.-I., Wen, H.
10.1101/2021.12.30.474592 — Posted: 2022-01-04
Structural basis of Omicron neutralization by affinity-matured public antibodies
Sheward, D. J., Pushparaj, P., Das, H., Kim, C., Kim, S., Hanke, L., Dyrdak, R., McInerney, G. M., Albert, J., Murrell, B., Karlsson Hedestam, G. B., Hällberg, B. M.
10.1101/2022.01.03.474825 — Posted: 2022-01-04
Structural and computational insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
wang, x., Wang, T., Ge, J., Zhang, L., Lan, J., He, X., Ren, Y., Wang, Z., Zhou, H., Fan, S., Zhu, C., Liu, D., Shao, B., Liu, T.-Y., Wang, Q.
10.1101/2022.01.03.474855 — Posted: 2022-01-04
Host kinase CSNK2 is a target for inhibition of pathogenic β-coronaviruses including SARS-CoV-2
Yang, X., Dickmander, R. J., Bayati, A., Taft-Benz, S. A., Smith, J. L., Brown, J. W., Lenarcic, E. M., Yount, B. L., Chang, E., Axtman, A. D., Baric, R. S., Heise, M. T., McPherson, P. S., Moorman, N. J., Willson, T. M.
10.1101/2022.01.03.474779 — Posted: 2022-01-04
A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and Omicron
Yuan, T. Z., Lucas, C., Monteiro, V. S., Iwasaki, A., Yang, M. L., Nepita, H. F., Lujan Hernandez, A. G., Taft, J. M., Frei, L., Reddy, S. T., Weber, C., Malobisky, K. P., Mesquita, R., Sato, A.
10.1101/2022.01.04.474803 — Posted: 2022-01-04
Maternal cytokine response after SARS-CoV-2 infection during pregnancy
Gigase, F. A. J., Molenaar, N. M., Missall, R. D., Rommel, A.-S., Lieb, W., Ibroci, E., Ohrn, S., Lynch, J., Krammer, F., Brody, R., Jessel, R. H., Sperling, R. S., Lesseur, C., Callipari, F., Galang, R. R., Snead, M. C., Janevic, T., Stone, J., Howell, E. A., Chen, J., Pop, V. J. M., Dolan, S. M., Bergink, V., De Witte, L. D.
10.1101/2022.01.04.474908 — Posted: 2022-01-04
Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates
Bojkova, D., Widera, M., Ciesek, S., Wass, M. N., Michaelis, M., Cinatl, J. N.
10.1101/2022.01.03.474773 — Posted: 2022-01-04
The SARS-CoV-2 infection in Thailand: analysis of spike variants complemented by protein structure insights
Ittisoponpisan, S., Yahangkiakan, S., Sternberg, M. J. E., David, A.
10.1101/2022.01.01.474713 — Posted: 2022-01-04
Safety and immunogenicity of a heterologous boost with a recombinant vaccine, NVSI-06-07, in the inactivated vaccine recipients from UAE: a phase 2 randomised, double-blinded, controlled clinical trial
AlKaabi, N., Yang, Y. K., Zhang, J., Xu, K., Liang, Y., Kang, Y., Su, J. G., Yang, T., Hussein, S., ElDein, M. S., Shao, S., Yang, S. S., Lei, W., Gao, X. J., Jiang, Z., Wang, H., Li, M., Mekki, H. M., Zaher, W., Mahmoud, S., Zhang, X., Qu, C., Liu, D. Y., Zhang, J., Yang, M., ElTantawy, I., Xiao, P., Wang, Z. N., Yin, J. L., Mao, X. Y., Zhang, J., Liu, N., Shen, F. J., Qu, L., Zhang, Y. T., Yang, X. M., Wu, G., Li, Q. M.
10.1101/2021.12.29.21268499 — Posted: 2022-01-04

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).